Version 1
: Received: 12 November 2023 / Approved: 13 November 2023 / Online: 13 November 2023 (10:37:37 CET)
How to cite:
Hasan, A.; Miller, D. D.; Stewart, M. W. Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and Challenges. Preprints2023, 2023110789. https://doi.org/10.20944/preprints202311.0789.v1
Hasan, A.; Miller, D. D.; Stewart, M. W. Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and Challenges. Preprints 2023, 2023110789. https://doi.org/10.20944/preprints202311.0789.v1
Hasan, A.; Miller, D. D.; Stewart, M. W. Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and Challenges. Preprints2023, 2023110789. https://doi.org/10.20944/preprints202311.0789.v1
APA Style
Hasan, A., Miller, D. D., & Stewart, M. W. (2023). Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and Challenges. Preprints. https://doi.org/10.20944/preprints202311.0789.v1
Chicago/Turabian Style
Hasan, A., Darby D Miller and Michael W. Stewart. 2023 "Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and Challenges" Preprints. https://doi.org/10.20944/preprints202311.0789.v1
Abstract
Pathologic angiogenesis is responsible for much of the vision loss that stems from several chorioretinal vascular diseases including neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Because vascular endothelial growth factor (VEGF) serves as a pivotal angiogenic molecule, it has emerged as the primary target for therapeutic drugs. Current anti-VEGF therapy is dominated by bevacizumab, ranibizumab, and aflibercept, all of which have been available for more than a decade, but new drugs, both biosimilars (Byooviz and Cimerli) and drugs whose primary aim is to decrease treatment burden (brolucizumab, faricimab, and the ranibizumab port delivery system), have been approved. Recent failures (conbercept, abicipar, and KSI-301) emphasize the complexity of drug development and the difficulties faced by innovators. Most therapies under development, including tyrosine kinase inhibitors and gene therapy, include VEGF-A blockade as their primary function and aim to extend durability rather than increase peak efficacy. But even as many new drugs look to extend durability, cost containment with mandated use of biosimilars serves to balance the therapeutic landscape.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
